Peter M Moyle
Overview
Explore the profile of Peter M Moyle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rivera-Hernandez T, Carnathan D, Richter J, Marchant P, Cork A, Elangovan G, et al.
Vaccines (Basel)
. 2024 Apr;
12(4).
PMID: 38675764
Vaccine development against group A (GAS) has gained traction in the last decade, fuelled by recognition of the significant worldwide burden of the disease. Several vaccine candidates are currently being...
2.
Sinclair F, Begum A, Dai C, Toth I, Moyle P
Drug Deliv Transl Res
. 2023 Mar;
13(5):1500-1519.
PMID: 36988873
The CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 genome editing system has been a major technological breakthrough that has brought revolutionary changes to genome editing for therapeutic and diagnostic purposes...
3.
Alharthi S, Ziora Z, Janjua T, Popat A, Moyle P
Pharmaceutics
. 2022 May;
14(5).
PMID: 35631572
This study aimed to develop synergistic therapies to treat superbug infections through the encapsulation of sortase A inhibitors (SrtAIs; -chalcone (TC), curcumin (CUR), quercetin (QC), or berberine chloride (BR)) into...
4.
Alavi S, Cabot P, Raza A, Moyle P
Bioconjug Chem
. 2021 Apr;
32(4):810-820.
PMID: 33843208
Glucagon-like peptide-1 GLP-1 is a gut-derived peptide secreted from pancreatic β-cells that reduces blood glucose levels and body weight; however, native GLP-1 (GLP-1(7-36)-NH and GLP-1(7-37)) have short circulation half-lives (∼2...
5.
Rivera-Hernandez T, Carnathan D, Jones S, Cork A, Davies M, Moyle P, et al.
mBio
. 2020 Dec;
11(6).
PMID: 33262263
No abstract available.
6.
Andrzejewski S, Moyle P, Stringer B, Steel J, Layton C
Gene Ther
. 2020 Jun;
28(5):242-255.
PMID: 32541928
Neutralising antibodies (NAbs), caused by past adeno-associated virus (AAV) infection, represent a critical challenge for AAV-mediated gene therapy, with even low NAb titres capable of inhibiting gene transfer, however in...
7.
Maqbool F, Falconer J, Moyle P
Nanomedicine (Lond)
. 2020 Jun;
PMID: 32484025
To develop albendazole (ABZ)-loaded bombesin(6-14) (BBN(6-14)) functionalized liposomes for targeting GRPR to enhance delivery to cancer cells. ABZ-loaded liposomes were formulated using supercritical CO technology; functionalized with a GRPR-targeted lipid-anchored...
8.
Xu Z, Rivera-Hernandez T, Chatterjee O, Walker M, Moyle P
J Control Release
. 2019 Nov;
317:96-108.
PMID: 31758971
Protein antigens are, in general, weakly immunogenic, and therefore require co-delivery with adjuvants to stimulate potent immune responses. The fusion of (poly)peptide antigens to immunostimulatory adjuvants (e.g. Toll-like receptor (TLR)...
9.
Syed-Ab-Rahman S, Carvalhais L, Chua E, Chung F, Moyle P, Eltanahy E, et al.
Sci Total Environ
. 2019 Jul;
692:267-280.
PMID: 31349168
Biotic interactions through diffusible and volatile organic compounds (VOCs) are frequent in nature. Soil bacteria are well-known producers of a wide range of volatile compounds (both organic and inorganic) with...
10.
Hussein W, Cheong Y, Liu C, Liu G, Begum A, Attallah M, et al.
Nanotechnology
. 2019 Jul;
30(41):415604.
PMID: 31295734
The development of polymer-based nanoparticulate delivery systems for siRNA is important for the clinical success of gene therapy. However, there are some major drawbacks that need to be overcome. Short...